On 1 May 2016, DTID has started with a project through which the molecular landscape of Alzheimer’s disease (AD) that we built will be extended and refined. In collaboration with the Department of Human Genetics, Radboud University Medical Center, The Netherlands, we will also try to validate the key putative drug target from our AD landscape in fruit flies (Drosophila). This project is funded by a Dutch foundation.
Drug Target ID is a participant in the EU Innovative Medicines Initiative-2 (IMI-2) project PRISM that has started on 1 April 2016 and studies the (genetic and other) etiology of social withdrawal and related cognitive deficits as shared traits between Alzheimer’s disease, major depression and schizophrenia. For more information about the scope and aims of the project, see the following news article in Science:
In collaboration with the Department of Molecular Animal Physiology, Radboud University Nijmegen, The Netherlands, DTID is involved in a project to extend and refine our molecular landscape of multiple sclerosis (MS). In addition and in collaboration with Dr. Valentina Fossati of the New York Stem Cell Foundation, NY, USA, the MS landscape will be validated through experiments in stem cells derived from MS patients and involving the testing of three novel putative MS drugs modulating key targets in the MS landscape. This project has started on 1 March 2016 and is funded by the Dutch National MS Fund (‘Nationaal MS Fonds’). For more information (in Dutch), see:
From 1 August 2015 onwards and together with the SME orikami (www.orikami.nl), we make a digital version of the molecular landscape of multiple sclerosis (MS) and an online platform for personalized MS health care. This two-year project, DiaPro MS-app, is supported by EU-EFRO OP-Oost (project number PROJ-00217).
As a partner of the EU FP7 research project MATRICS (www.atrics-project.eu), we build a molecular landscape of aggression/conduct disorder (CD).
As part of the EU FP7 research project TS-EUROTRAIN (www.ts-eurotrain.eu), we build a molecular landscape of Tourette syndrome (TS).
As part of the EU FP7 research project OPTMISTIC (www.optimistic-dm.eu), we build a molecular landscape of the muscular disease myotonic dystrophy type 1 (DM1).
On 20 October 2013, Dr Geert Poelmans, founder/director of DTID, received the 2013 Richard Todd Award for Child Psychiatric Genetics of the International Society of Psychiatric Genetics at the World Conference of Psychiatric Genetics in Boston, USA. The award was given to Geert for his “outstanding contribution to the genetics of child psychiatric disorders”, based on the ‘molecular landscape building approach’ that he developed.
For a project that is funded by a Dutch foundation, we have built an integrated molecular landscape of Alzheimer’s disease (AD).
For our industrial partner Synthon Biopharmaceuticals, Ltd, we have built a molecular landscape of biochemical signaling cascades for multiple sclerosis (MS).